Niagen Bioscience (NAGE) Operating Leases (2019 - 2026)
Niagen Bioscience (NAGE) posted quarterly Operating Leases of $1.5 million for Q1 2026, down 55.89% year-over-year from $3.5 million in Q1 2025, and down 14.93% quarter-over-quarter from $1.8 million in Q4 2025.
Niagen Bioscience (NAGE) Operating Leases (2019 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Operating Leases for 8 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 55.89% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (down 55.89% YoY), while the FY2025 annual figure was $1.8 million, down 30.19% from the prior year.
- Operating Leases slipped to $1.5 million in Q1 2026 per NAGE's latest filing, from $1.8 million in the prior quarter.
- Across five years, Operating Leases topped out at $4.5 million in Q2 2022 and bottomed at $1.5 million in Q1 2026.
- Historically, Operating Leases has averaged $3.1 million across 5 years, with a median of $3.1 million in 2023.
- Annual changes were most pronounced in 2022 — Operating Leases surged 180.24% — and 2026, when it sank 55.89%.
- Niagen Bioscience's Operating Leases stood at $3.5 million in 2022, then dropped by 27.58% to $2.6 million in 2023, then grew by 1.44% to $2.6 million in 2024, then tumbled by 30.19% to $1.8 million in 2025, then slipped by 14.93% to $1.5 million in 2026.
- Business Quant data shows NAGE's Operating Leases at $1.5 million in Q1 2026, $1.8 million in Q4 2025, and $2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Niagen Bioscience | 238.30 Mn | 171.56 Mn | 19.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.33 Mn |
| Mar 31, 2026 | 1.54 Mn |
| Dec 31, 2025 | 1.82 Mn |
| Sep 30, 2025 | 2.08 Mn |
| Jun 30, 2025 | 3.29 Mn |
| Mar 31, 2025 | 3.50 Mn |
| Dec 31, 2024 | 2.60 Mn |
| Sep 30, 2024 | 2.90 Mn |
| Jun 30, 2024 | 3.11 Mn |
| Mar 31, 2024 | 3.20 Mn |
| Dec 31, 2023 | 2.56 Mn |
| Sep 30, 2023 | 2.91 Mn |
| Jun 30, 2023 | 3.14 Mn |
| Mar 31, 2023 | 4.05 Mn |
| Dec 31, 2022 | 3.54 Mn |
| Sep 30, 2022 | 3.69 Mn |
| Jun 30, 2022 | 4.53 Mn |
| Mar 31, 2022 | 4.01 Mn |
| Dec 31, 2021 | 4.70 Mn |
| Sep 30, 2021 | 3.30 Mn |